TCRX
Tscan Therapeutics Inc
NASDAQ: TCRX · HEALTHCARE · BIOTECHNOLOGY
$1.15
-8.73% today
Updated 2026-04-29
Market cap
$75.73M
P/E ratio
—
P/S ratio
7.33x
EPS (TTM)
$-1.00
Dividend yield
—
52W range
$1 – $3
Volume
0.9M
Tscan Therapeutics Inc (TCRX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $1.08M | $10.14M | $13.54M | $21.05M | $2.82M | $10.32M |
| Revenue growth (YoY) | — | — | +834.7% | +33.5% | +55.5% | -86.6% | +266.7% |
| Cost of revenue | $9.44M | $20.58M | $3.33M | $5.14M | $88.15M | $4.11M | $2.87M |
| Gross profit | $-9.44M | $-19.49M | $10.14M | $13.54M | $21.05M | $2.82M | $7.46M |
| Gross margin | — | -1796.5% | 100.0% | 100.0% | 100.0% | 100.0% | 72.2% |
| R&D | $9.44M | $20.58M | $44.95M | $59.82M | $88.15M | $107.35M | $114.15M |
| SG&A | $4.77M | $6.74M | $13.83M | $20.35M | $25.49M | $29.56M | $31.99M |
| Operating income | $-14.21M | $-26.23M | $-48.64M | $-66.64M | $-93.46M | $-134.82M | $-135.81M |
| Operating margin | — | -2417.8% | -479.6% | -492.3% | -444.0% | -4787.7% | -1315.4% |
| EBITDA | $-13.69M | $-25.00M | $-45.30M | $-59.91M | $-80.10M | $-119.74M | $-132.95M |
| EBITDA margin | — | -2304.4% | -446.7% | -442.6% | -380.5% | -4252.1% | -1287.6% |
| EBIT | $-14.21M | $-26.23M | $-48.63M | $-65.05M | $-85.46M | $-123.85M | $-135.81M |
| Interest expense | $0.00 | $0.00 | $16000.00 | $1.18M | $3.76M | $3.65M | $2.77M |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-13.66M | $-26.13M | $-48.63M | $-66.22M | $-89.22M | $-127.50M | $-129.77M |
| Net income growth (YoY) | — | -91.3% | -86.1% | -36.2% | -34.7% | -42.9% | -1.8% |
| Profit margin | — | -2408.0% | -479.5% | -489.3% | -423.9% | -4527.7% | -1256.8% |